Deadline: 11-Dec-2025
Pfizer has announced a Request for Proposals for its 2026 Vaccine Access and Global CDI (Clostridioides difficile infection) program aimed at improving vaccine access and addressing global health challenges.
The focus areas include improving vaccine access in underserved populations, supporting innovative solutions for vaccine delivery, increasing awareness and education around vaccines, strengthening health systems to enhance vaccine uptake, and reducing the burden of Clostridioides difficile infection worldwide. The priorities emphasize sustainable impact, alignment with global health goals, fostering partnerships, and encouraging scalable initiatives.
Eligible countries for this opportunity are the United States, United Kingdom, France, Germany, and Japan. Projects may request funding of up to $500,000 USD and must be completed within a 12-month timeframe. Applicants must be based in one of the eligible countries, and only organizations—not individuals or unaffiliated medical practice groups—are permitted to apply.
Applicants must have a Principal Investigator with a relevant degree such as MD, PhD, or equivalent in fields like nursing, pharmacy, physiotherapy, or social work. The PI must be employed or contracted by the requesting organization and be prepared to act as the lead or designate for the project. The organization must also be legally capable of receiving direct funding from Pfizer Inc.
If selected, grantees must be willing to enter into a research collaboration with Pfizer, which may involve Pfizer’s participation in project design, protocol development, and research monitoring. Projects involving multiple institutions are permitted, provided the lead organization plays a central role in coordination and delivery. Priority will be given to those open to collaborative partnerships with other institutions conducting similar research
For more information, visit Pfizer.